A candidate molecular signature associated with tamoxifen failure in primary breast cancer

Breast Cancer Research

Table 6 Statistical comparison of the mRNA levels measured by RTQ-PCR between the nonrelapsing and relapsing groups of tumor samples from the independent cohort (Centre Léon Bérard, Lyon, France)

Genes	Tumor samples	Number of samples	mRNA levels (arbitrary units)
			Median	Range	P ^a
ESR1	Nonrelapsing	19	117.9	0.33 to 472.35	0.0001
	Relapsing	14	2.55	0.03 to 51.75
IGFBP4	Nonrelapsing	19	97.52	0.02 to 12691.41	0.02
	Relapsing	14	1.40	0.01 to 7282.33
MET	Nonrelapsing	19	0.10	0.08 to 10.26	NS (0.33)
	Relapsing	14	0.12	0.10 to 2.28
FOS	Nonrelapsing	19	8.72	0.03 to 47.92	0.0001
	Relapsing	14	0.28	0.01 to 1.46
SNCG	Nonrelapsing	19	5.99	0.04 to 915.74	0.005
	Relapsing	14	0.52	0.01 to 18.28
BCL2	Nonrelapsing	19	5.59	0.01 to 17.24	0.0004
	Relapsing	14	0.12	0.01 to 8.57

^aP value (Mann-Whitney test) was considered significant when P < 0.05. NS, not significant; RTQ-PCR, real-time quantitative PCR.

ISSN: 1465-542X